Selskabsmeddelelse16.09.2024, 20.00Asarina Pharma AB (publ) shares to be delisted and the last day of trading is 1 October 2024
Selskabsmeddelelse21.08.2024, 11.30Bulletin from the extraordinary general meeting and first control meeting in Asarina Pharma
Selskabsmeddelelse22.07.2024, 08.00NOTICE OF EXTRAORDINARY GENERAL MEETING AND FIRST CONTROL MEETING IN ASARINA PHARMA AB (PUBL)
Selskabsmeddelelse18.07.2024, 17.45ASARINA PHARMA ANNOUNCES OUTCOME OF PARTNERING PROCESS, CONTROL BALANCE SHEET AND PROPOSAL TO LIQUIDATE
Selskabsmeddelelse27.06.2024, 11.33Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)
Selskabsmeddelelse28.05.2024, 22.00Asarina Pharma AB announces new date for the release of Annual Report for 2023
Selskabsmeddelelse21.05.2024, 11.50Asarina Pharma AB announces new date for the release of Annual Report for 2023
Selskabsmeddelelse30.11.2023, 10.30Asarina Pharma AB changes Certified Adviser to Carnegie Investment Bank AB
Selskabsmeddelelse23.08.2023, 08.30Asarina Pharma AB (publ) releases First Half-Year Report (H1/2023)
Selskabsmeddelelse23.05.2023, 09.02Positive Tourette Syndrome results to be presented at ESSTS, 15th European Conference on Tourette Syndrome and Tic Disorders
Selskabsmeddelelse22.05.2023, 11.15Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)
Selskabsmeddelelse05.05.2023, 13.33Asarina Pharma's positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America
Selskabsmeddelelse18.04.2023, 10.39Asarina Pharma: NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL)
Selskabsmeddelelse01.04.2023, 14.20Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome